- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Mankind Pharma, RDIF ink pact for Sputnik V sale in India
New Delhi: The Covid-19 vaccine, Sputnik V is now likely to be rolled out in India by Delhi-based Mankind Pharma apart from Dr Reddy's Laboratories, as the drugmaker has recently struck a deal with the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund for sales and distribution of the drug.
According to a recent media report in Economic Times, the announcement to this effect would be made by next week.
On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform.
In September, RDIF entered into a partnership with Dr Reddy's Laboratories to conduct clinical trials of the Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy's regulatory approval in India.
Also Read: Dr Reddys, RDIF Get DCGI Nod For Russian Covid Vaccine Trial
The Hyderabad-based drugmaker secured the Drug Control General of India (DCGI) nod to conduct an adaptive phase 2/3 human clinical trial for the Sputnik V vaccine in India on October 18. This will be a multicenter and randomized controlled study, which will include safety and immunogenicity study.
While Dr Reddy's and RDIF initially planned to conduct Phase 3 trials of the vaccine, but the subject expert committee (SEC) of the Central Drugs Standards Control Organization (CDSCO) which is looking into Covid related proposals asked Dr Reddy's to conduct a Phase 2 and 3 clinical trials in India, instead of just a phase 3 study.
However, it reapplied with a revised protocol, and subsequently got permission and will now start phase II and III human clinical trials involving 1,500 participants in India.
Meanwhile, RDIF has reached agreements with Indian manufacturers to produce 300 million doses of the shot.
"The co-operation agreement has been signed for sales and distribution of much anticipated Covid-19 vaccine Sputnik V with RDIF by Mankind pharma," sources told ET without disclosing many details on the agreement.
Russia, the first country to grant regulatory approval for a novel coronavirus vaccine. It is also conducting Phase III trials of Sputnik V in Belarus, Venezuela and the United Arab Emirates, the daily reports.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751